Research News

Transcriptional repression by a secondary DNA binding surface of DNA topoisomerase I safeguards against hypertranscription

A team of scientists, led by N2CR member Dr. Tee Wee Wei, has identified the enzyme DNA topoisomerase I (TOP1) as a key regulator of gene activity crucial for normal development and health. Their discovery reveals that a specific disease-associated mutation (R548Q) in TOP1 accelerates gene activity, disrupting normal developmental programs. Tight control of gene activity is essential, as dysregulation can contribute to diseases, particularly in aggressive cancers characterized by transcriptional overdrive. Importantly, the mutation does not impact TOP1’s primary enzymatic function but hinders its ability to bind to DNA correctly. This research highlights TOP1 as a molecular rheostat, ensuring precise control of gene activity levels and maintaining appropriate total transcription levels in our cells.

Read more here: https://www.nature.com/articles/s41467-023-42078-9

Share this story:
Facebook
Twitter
LinkedIn

Related Research News

Research News

Predicting CLL Treatment with BCL-2 Dependence

Chronic lymphocytic leukemia (CLL) is a type of cancer that affects the blood and bone marrow, leading to the buildup …

Read More →
Research News

One Month of Brief Weekly Magnetic Field Therapy Enhances the Anticancer Potential of Female Human Sera

Muscle is our first line of defence against cancer. A randomised clinical trial in Singapore, led by N2CR members A/Prof …

Read More →
Research News

Efficacy of Combined Pembrolizumab and Bevacizumab in Platinum-Resistant Nasopharyngeal Carcinoma

Nasopharyngeal carcinoma (NPC) is common in South China and parts of Southeast Asia. Despite treatment, 20-30% of patients relapse within …

Read More →